Exact claim · Version 1 · Reviewed 2026-07-23
“Tesamorelin is an approved general weight-loss drug.”
A verdict on this wording and scope, not a universal grade for Tesamorelin.
01 · Verdict
Misleading
The label specifically says it is not indicated for weight-loss management.
- Evidence basis
- Regulatory or product record
- Scope
- The current Egrifta SV and Egrifta WR labels.
- Category
- Approval and status
02 · Primary record
Check the attached evidence
01EGRIFTA SV (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the corrective verdict02EGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the corrective verdict
Supports the corrective verdict02EGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the corrective verdict
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.